$3.16 \pm 1.05$ 

 $0.220 \pm 0.073$ 

 $0.922 \pm 0.814$ 

 $1.23 \pm 0.49$ 

22700 ± 2700

6620 ± 4250

7180 ± 2670

5360 ± 1900

2650 ± 310

6

2400

Male

	Treatment Group (mg/kg)			
	20 IV Plasma <sup>a</sup>	20 Gavage Plasma <sup>b</sup>	60 Gavage Plasma <sup>b</sup>	
C_Omin_pred (ng/mL)	62500 ± 14600			
Cmax_obs (ng/mL)	33700	1360	7830	
Cmax_pred (ng/mL)		756 ± 119	5530 ± 1250	
Tmax_obs (hour)		0.0833	0.0833	
Tmax_pred (hour)		$0.131 \pm 0.030$	0.103 ± 0.057	
Alpha Half-life (hour)	0.0645 ± 0.0093	0.119 ± 0.118	0.156 ± 0.071	
Beta Half-life (hour)	0.435 ± 0.025	0.895 ± 0.247	0.789 ± 0.185	
k01 (hour <sup>-1</sup> )		$11.0 \pm 11.4$	19.4 ± 20.6	
k01 Half-life (hour)		0.0631 ± 0.0655	0.0358 ± 0.0381	

3.46 ± 2.75

 $1.82 \pm 2.68$ 

 $1.30 \pm 0.64$ 

46800 ± 4900

 $24700 \pm 18400$ 

 $13600 \pm 11100$ 

 $19000 \pm 7400$ 

427 ± 45

426

 $0.201 \pm 0.160$ 

8.71 ± 1.21

 $1.65 \pm 0.46$ 

 $1.97 \pm 0.18$ 

2790 ± 340

529 ± 157

320 ± 75

269 ± 65

7180 ± 880

6440

 $0.211 \pm 0.022$ 

 $0.0796 \pm 0.0111$ 

k10 (hour-1)

k12 (hour-1)

k21 (hour<sup>-1</sup>) Cl1 (mL/hr/kg)

V1 (mL/kg)

V2 (mL/kg)

V1\_F (mL/kg)

V2 F (mL/kg)

AUC 0-T (mL\*hr)

AUCinf\_pred (ng/mL\*hr)

MRT (hour)

F (percent)

Cl2 (mL/hr/kg)

Cl1\_F (mL/hr/kg) Cl2 F (mL/hr/kg)

k10 Half-life (hour)

Species/Strain: Mouse/B6C3F1/N

Toxicokinetics Data Summary

Request Date: 7/11/2023 Request Time: 10:03:16 Lab: Battelle Columbus

Compound: N-Butylbenzenesulfonamide CAS Number: 3622-84-2

#### Male

# Treatment Group (mg/kg)

200 Gavage Plasma<sup>b</sup> 200 Gavage Plasma<sup>c</sup>

C_0min_pred (ng/mL)		
Cmax_obs (ng/g)	17800	17800
Cmax_pred (ng/mL)	15500 ± 2400	15500 ± 2300
Tmax_obs (hour)	0.167	0.167
Tmax_pred (hour)	$0.136 \pm 0.051$	0.134 ± 0.050
Alpha Half-life (hour)	0.262 ± 0.055	0.268 ± 0.054
Beta Half-life (hour)	1.97 ± 0.31	$2.10 \pm 0.50$
k01 (hour-1)	16.1 ± 10.5	16.6 ± 10.7
k01 Half-life (hour)	$0.0431 \pm 0.0281$	0.0417 ± 0.0268
k10 (hour-1)	2.18 ± 0.40	2.14 ± 0.38
k10 Half-life (hour)	0.317 ± 0.058	0.323 ± 0.057
k12 (hour-1)	0.384 ± 0.161	0.373 ± 0.153
k21 (hour <sup>-1</sup> )	0.426 ± 0.084	0.398 ± 0.110
Cl1 (mL/hr/kg)		
Cl2 (mL/hr/kg)		
Cl1_F (mL/hr/kg)	19900 ± 1900	19800 ± 1800
Cl2_F (mL/hr/kg)	3500 ± 1170	3450 ± 1130
V1 (mL/kg)		
V2 (mL/kg)		
V1_F (mL/kg)	9120 ± 2020	9250 ± 1950
V2_F (mL/kg)	8200 ± 1940	8660 ± 2150
MRT (hour)		
AUC_0-T (mL*hr)	10500	10500
AUCinf_pred (ng/mL*hr)	10000 ± 900	10100 ± 900
F (percent)	14	14

Experiment Number: K10482B	periment Number: K10482B Toxicokinetics Data Summary		
Route: IV, Gavage, Dosed Feed Compound: N-Butylbenzenesulfonamide		Request Time: 10:03:16	
Species/Strain: Mouse/B6C3F1/N CAS Number: 3622-84-2		Lab: Battelle Columbus	
Male			

Treatment Group (ppm)				
500 Dosed Feed Plasma <sup>d</sup> 500 Dosed Feed Plasma <sup>e</sup> 1000 Dosed Feed Plasma <sup>d</sup>				

Cmax_obs (ng/mL)	26.7	26.7	44.6
Tmax_obs (hour)	0	0	0.5
Half-life (hour)	2.36	1.06	4.04
AUC_0-T (ng/mL*hr)	28.6	25.4	70.7
AUCinf_pred (ng/mL*hr)	30.9	25.8	72.2

Experiment Number: K10482B Toxicokinetics Data Summary		<b>Request Date:</b> 7/11/2023	
Route: IV, Gavage, Dosed Feed Compound: N-Butylbenzenesulfonamide		Request Time: 10:03:16	
Species/Strain: Mouse/B6C3F1/N	Lab: Battelle Columbus		
Male			

	_	
Treatment	Group	(ppm)

1000 Dosed Feed Plasma<sup>f</sup> 1000 Dosed Feed Plasma<sup>d</sup> 1000 Dosed Feed Plasma<sup>f</sup>

Cmax_obs (ng/mL)	44.6	186	186
Tmax_obs (hour)	0.5	0	0
Half-life (hour)	2.09	4.17	2.28
AUC_0-T (ng/mL*hr)	67.4	117	109
AUCinf_pred (ng/mL*hr)	68.1	121	111

**Experiment Number:** K10482B **Route:** IV, Gavage, Dosed Feed Toxicokinetics Data Summary Compound: N-Butylbenzenesulfonamide Request Date: 7/11/2023 Request Time: 10:03:16 Lab: Battelle Columbus

Species/Strain: Mouse/B6C3F1/N

CAS Number: 3622-84-2

Treatment Group (mg/kg)				
	20 IV Plasma <sup>g</sup>	20 IV Plasma <sup>h</sup>	20 Gavage Plasma <sup>b</sup>	20 Gavage Plasma <sup>i</sup>
C_0min_pred (ng/mL)	60800 ± 17000	60500 ± 59200		
Cmax_obs (ng/mL)	10700	29900	779	779
Cmax_pred (ng/mL)			$1040 \pm 190$	871 ± 175
Tmax_obs (hour)			0.0333	0.0333
Tmax_pred (hour)			$0.107 \pm 0.027$	0.0710 ± 0.0232
Alpha Half-life (hour)	$0.110 \pm 0.018$	0.0270 ± 0.0159	$0.121 \pm 0.045$	0.0588 ± 0.0836
Beta Half-life (hour)	0.648 ± 0.189	0.298 ± 0.020	4.13 ± 7.60	0.490 ± 0.116
k01 (hour-1)			14.5 ± 9.3	19.0 ± 31.9
k01 Half-life (hour)			0.0477 ± 0.0303	0.0364 ± 0.0610
k10 (hour-1)	5.94 ± 0.88	13.1 ± 9.3	3.48 ± 2.51	6.68 ± 8.60
k10 Half-life (hour)	0.117 ± 0.017	0.0529 ± 0.0377	$0.199 \pm 0.144$	0.104 ± 0.134
k12 (hour-1)	0.306 ± 0.183	10.4 ± 7.0	2.14 ± 1.49	4.02 ± 7.76
k21 (hour-1)	1.14 ± 0.36	4.57 ± 1.23	0.276 ± 0.386	2.50 ± 1.01
Cl1 (mL/hr/kg)	1960 ± 340	4330 ± 1280		
Cl2 (mL/hr/kg)	101 ± 58	3430 ± 2230		
Cl1_F (mL/hr/kg)			36900 ± 18900	74000 ± 8300
Cl2_F (mL/hr/kg)			22800 ± 17700	44600 ± 32000
V1 (mL/kg)	329 ± 92	331 ± 323		
V2 (mL/kg)	88.5 ± 37.4	750 ± 311		
V1_F (mL/kg)			10600 ± 4100	11100 ± 14500
V2_F (mL/kg)			82400 ± 174000	17900 ± 8100
MRT (hour)	0.214 ± 0.026	0.249 ± 0.067		
AUC_0-T (mL*hr)	3320	3320	259	259
AUCinf_pred (ng/mL*hr)	10200 ± 1800	4620 ± 1370	541 ± 277	270 ± 30
F (percent)				

**Experiment Number:** K10482B **Route:** IV, Gavage, Dosed Feed Toxicokinetics Data Summary Compound: N-Butylbenzenesulfonamide Request Date: 7/11/2023 Request Time: 10:03:16 Lab: Battelle Columbus

Species/Strain: Mouse/B6C3F1/N

CAS Number: 3622-84-2

#### Female

	Treatment Group (mg/kg)		
	6 <b>0 Gavage Plasma</b> <sup>b</sup>	200 Gavage Plasma <sup>₅</sup>	200 Gavage Plasma <sup>j</sup>
C_0min_pred (ng/mL)			
Cmax_obs (ng/mL)	2950	16100	16100
Cmax_pred (ng/mL)	2960 ± 430	13700 ± 2300	14900 ± 2500
Tmax_obs (hour)	0.0833	0.0833	0.0833
Tmax_pred (hour)	$0.107 \pm 0.038$	0.133 ± 0.075	$0.191 \pm 0.065$
Alpha Half-life (hour)	0.177 ± 0.042	$0.354 \pm 0.119$	$0.310 \pm 0.173$
Beta Half-life (hour)	0.737 ± 0.135	$1.00 \pm 0.23$	3.12 ± 18.1
k01 (hour-1)	19.1 ± 12.5	20.0 ± 18.1	10.3 ± 8.0
k01 Half-life (hour)	0.0362 ± 0.0236	0.0347 ± 0.0314	0.0674 ± 0.0522
k10 (hour-1)	3.14 ± 0.56	$1.60 \pm 0.35$	1.94 ± 1.35
k10 Half-life (hour)	0.221 ± 0.039	0.432 ± 0.093	0.358 ± 0.249
k12 (hour-1)	0.544 ± 0.300	0.200 ± 0.206	0.264 ± 0.313
k21 (hour-1)	1.17 ± 0.31	0.844 ± 0.316	0.256 ± 1.44
Cl1 (mL/hr/kg)			
Cl2 (mL/hr/kg)			
Cl1_F (mL/hr/kg)	43000 ± 3500	18500 ± 1900	17100 ± 6100
Cl2_F (mL/hr/kg)	7460 ± 3250	2310 ± 2030	2340 ± 3480
V1_F (mL/kg)	13700 ± 2900	11500 ± 2700	8860 ± 3570
V2_F (mL/kg)	6360 ± 1650	2730 ± 1610	9130 ± 64500
MRT (hour)			
AUC_0-T (mL*hr)	1340	11300	11300
AUCinf_pred (ng/mL*hr)	1390 ± 110	10800 ± 1100	11700 ± 4200
F (percent)	6	25	25

Experiment Number: K10482B	Toxicokinetics Data Summary	<b>Request Date:</b> 7/11/2023	
Route: IV, Gavage, Dosed Feed	vage, Dosed Feed Compound: N-Butylbenzenesulfonamide		
Species/Strain: Mouse/B6C3F1/N CAS Number: 3622-84-2		Lab: Battelle Columbus	
	Male		
	Treatment Group (mg/kg)		

20 IV Brain<sup>k</sup>

Cmax_obs (ng/g)	66800	1260	8280	23400
Tmax_obs (hour)	0.0669	0.118	0.120	0.198
Half-life (hour)	0.183	0.315	0.417	0.524
AUC_0-T (ng/g*hr)	20400	258	2390	14100
AUCinf_pred (ng/g*hr)	20500	279	2430	14200

20 Gavage Brain<sup>1</sup>

60 Gavage Brain<sup>1</sup>

200 Gavage Brain<sup>1</sup>

xperiment Number: K10482B Route: IV, Gavage, Dosed Feed Species/Strain: Mouse/B6C3F1/N	Toxicokinetics Data Summary Compound: N-Butylbenzenesulfonamide CAS Number: 3622-84-2			Request Date: 7/11/2023 Request Time: 10:03:16 Lab: Battelle Columbus				
		Female						
	Treatment Group (mg/kg)							
	20 IV Brain <sup>k</sup>	20 IV Brain <sup>m</sup>	20 Gavage Brain <sup>1</sup>	60 Gavage Brain <sup>1</sup>	200 Gavage Brain <sup>1</sup>			
Cmax_obs (ng/g)	15700	45900	733	2830	18700			
Tmax_obs (hour)	0.0738	0.0738	0.199	0.198	0.362			
Half-life (hour)	0.352	0.352	0.278	0.329	0.545			
AUC_0-T (ng/g*hr)	4110	14600	208	1270	16600			
AUCinf_pred (ng/g*hr)	4150	14600	222	1280	16600			

#### LEGEND

#### MODELING SOFTWARE

Phoenix WinNonlin, Version 6.3, 6.4 and 8.0

#### MODELING METHOD & BEST FIT MODEL

<sup>a</sup>WinNonlin, Versions 6.3 and 6.4, Pharsight Corporation, Mountain View, CA (Parameter estimates are reported to three significant figures. Observed values do not have a reported SEM.), two-compartment with bolus input, first order elimination and 1/Yhat2 weighting (Model #8) <sup>b</sup>WinNonlin, Versions 6.3 and 6.4, Pharsight Corporation, Mountain View, CA. (Parameter estimates are reported to three significant figures. Observed values do not have a reported SEM.) two-compartment model with first order input, first order elimination, and 1/Yhat2 weighting (Model #13)

<sup>c</sup>WinNonlin, Versions 6.3 and 6.4, Pharsight Corporation, Mountain View, CA (Parameter estimates are reported to three significant figures. Observed values do not have a reported SEM.), two-compartment model with first order input, first order elimination, and 1/Yhat2 weighting (Model #13). Does not include the single concentration at 12 hours.

<sup>d</sup>Phoenix WinNonlin, Version 8.0, Certara L.P., Princeton, NJ library models, non-compartmental analysis, no weighting factor.

<sup>e</sup>Phoenix WinNonlin, Version 8.0, Certara L.P., Princeton, NJ library models, non-compartmental analysis, no weighting factor, analyzed without the 8-hour time point.

<sup>f</sup>Phoenix WinNonlin, Version 8.0, Certara L.P., Princeton, NJ library models, non-compartmental analysis, no weighting factor, analyzed without the 18-hour time point.

<sup>g</sup>WinNonlin, Versions 6.3 and 6.4, Pharsight Corporation, Mountain View, CA. (Parameter estimates are reported to three significant figures. Observed values do not have a reported SEM.), two-compartment model with bolus input, first order elimination, and 1/Yhat2 weighting (Model #8)

<sup>h</sup>WinNonlin, Versions 6.3 and 6.4, Pharsight Corporation, Mountain View, CA. (Parameter estimates are reported to three significant figures. Observed values do not have a reported SEM.), two-compartment model with bolus input, first order elimination, and 1/Yhat2 weighting (Model #8). Does not include the single concentration at 4 hours or two concentrations at 0.0333 hours

<sup>1</sup>WinNonlin, Versions 6.3 and 6.4, Pharsight Corporation, Mountain View, CA. (Parameter estimates are reported to three significant figures. Observed values do not have a reported SEM.), two-compartment model with first order input, first order elimination, and 1/Yhat2 weighting (Model #13). Does not include the single concentration at 4 hours.

<sup>j</sup>WinNonlin, Versions 6.3 and 6.4, Pharsight Corporation, Mountain View, CA. (Parameter estimates are reported to three significant figures. Observed values do not have a reported SEM.), two-compartment model with first order input, first order elimination, and 1/Yhat2 weighting (Model #13). Does not include the single concentration at 8 hours.

## MODELING METHOD & BEST FIT MODEL (cont'd)

<sup>k</sup>WinNonlin, Versions 6.3 and 6.4, Pharsight Corporation, Mountain View, CA. (Parameter estimates are reported to three significant figures. NCA does not calculate a standard error.), NCA model with bolus input, first order output, and uniform weighting.

<sup>1</sup>WinNonlin, Versions 6.3 and 6.4, Pharsight Corporation, Mountain View, CA. (Parameter estimates are reported to three significant figures. NCA does not calculate a standard error.), NCA model with first order input, first order output, and uniform weighting.

<sup>m</sup>WinNonlin, Versions 6.3 and 6.4, Pharsight Corporation, Mountain View, CA. (Parameter estimates are reported to three significant figures. NCA does not calculate a standard error.), NCA model with bolus input, first order output, and uniform weighting. Does not include two concentrations at 0.0333 hours.

#### TK PARAMETERS

- C\_Omin\_pred = Fitted plasma concentration at time zero (IV only)
- Cmax = Observed or Predicted Maximum plasma (or tissue) concentration
- Tmax = Time at which Cmax predicted or observed occurs
- Half-life = Lambda z Half life, t 1/2, the terminal elimination half-life based on non-compartmental analysis
- Alpha Half-Life = Half-life for the alpha phase
- Beta Half-life = Half-life for the beta phase
- k01 = Absorption rate constant, ka
- k01 Half-life = Half-life of the absorption process to the central compartment
- k10 = Elimination rate constant from the central compartment also ke or kelim
- k10 Half-life = Half-life for the elimination process from the central compartment
- k12 = Distribution rate constant from first to second compartment
- k21 = Distribution rate constant from third to central compartment
- Cl1 = Clearance of central compartment, Clapp or apparent clearance for intravenous groups
- Cl2 = Clearance of the secondary compartment
- Cl1\_F = Apparent clearance of the central compartment, also Cl\_F for gavage groups in non-compartmental model
- Cl2\_F = Apparent clearance of the secondary compartment
- V1 = Volume of distribution of the central compartment, includes Vd and V volume of distribution, Vz apparent volume of distribution NCA, Vapp apparent volume of distribution for intravenous studies

## TK\_PARAMETERS (cont'd)

V2 = Volume of distribution for the peripheral compartment

V1\_F = Apparent volume of distribution for the central compartment includes Vd\_F, V\_F for oral groups, and Vc\_F

V2\_F = Apparent volume of distribution for the peripheral compartment

MRT = Mean residence time

AUC\_0-T = Area under the plasma concentration versus time curve, AUC, from time ti (initial) to tf (final), AUClast

AUCinf\_pred = Area under the plasma concentration versus time curve, AUC, extrapolated to time equals infinity

F = Bioavailability, absolute bioavailability

## TK\_PARAMETERS PROTOCOL

## ANALYSIS METHOD

Blood and brain tissue samples were measured using gas chromatography with mass selective detection (GC/MSD). The target limit of quantitation (LOQ) for N-Butylbenzenesulfonamide (NBBS) (IV and gavage) in plasma was 2.5 ng/mL, for NBBS in brain was 25 ng/g tissue. Samples below the LOQ were designated as below the limit of quantitation (BLOQ).

## TK\_INTRAVENOUS PLASMA

## 20 mg/kg Male and Female

Mice were give a single intravenous dose in Cremophor:ethanol:deionized water (1:1:8) vehicle and allowed food and water ad libitum. Blood and brain samples were collected at 11 time points post-administration with n=3 per time point. Time points were pre-dose, 2, 5, 10, 15, 20, 30, 45, 60, 120, 180, and 240 min post-dose.

## TK\_PARAMETERS PROTOCOL (cont'd)

### TK\_GAVAGE PLASMA

### 20 mg/kg Male and Female

Mice were given a single oral gavage dose in 0.5% methylcellulose in deionized water vehicle and allowed food and water ad libitum. Blood and brain samples were collected at 11 time points post-administration with n=3 per time point. Time points were Pre-dose, 2, 5, 10, 15, 20, 30, 45, 60, 120, 240, and 480 min post-dose.

### 60 mg/kg, 200 mg/kg Male and Female

Mice were given a single oral gavage dose in 0.5% methylcellulose in deionized water vehicle and allowed food and water ad libitum. Blood and brain samples were collected at 11 time points post-administration with n=3 per time point. Pre-dose, 5, 10, 20, 30, 45, 60, 120, 240, 480, 720, and 1440 min post-dose.

#### TK\_DOSED\_FEED PLASMA

#### ANALYSIS METHOD

Whole blood was centrifuged to obtain plasma samples. Plasma samples were processed by liquid-liquid extraction with or without a ten-fold concentration step and analyzed by gas chromatography (GC) with mass selective detection (MSD). The original analytical method had a lower limit of quantitation (LLOQ) of 5 ng/mL with limit of detection (LOD) of 1.57 ng/mL but those samples that were without the ten-fold concentration step and were below the LOD or nondetected were reanalyzed using the ten-fold concentration step and different GC conditions. LLOQ for this second method was 0.5 ng/mL and the LOD was 0.149 ng/mL Samples below the LOD were designated as below the limit of detection (BLOD). For mice, the 500 ppm group had an increase in concentration at the last measurable time point of 8 hour and the 1000 and 2000 ppm groups had increases at their last measurable time point of 18 hours. These values affected the characterization of the terminal phases. Therefore, the 500 ppm group was also evaluated without the 8 hour time point, and the 1000 and 2000 ppm groups were also evaluated without the 8 hour time point. Parameter estimates are reported to three significant figures.

## TK\_PARAMETERS PROTOCOL (cont'd)

#### 500 ppm, 1000 ppm Male

Forty mice (11 weeks old and weighing 26.2 + or - 1.4g at randomization) were provided dosed feed for seven consecutive days at concentrations of 500, 1000, or 2000 ppm. Mice were fed irradiated NTP-2000 meal feed ad libitum and tap water was given ad libitum. The average daily food consumption for mice ranged from 4.2 to 4.8 g with standard deviations ranging from 0.8 to 1.4. Whole blood samples were collected at 0 (at removal of food), 0.5, 1, 2, 4, 6, 8, 10, 12, 18, and 24 hours post-dose (last day of dosing, N=3 mice/group/timepoint). The 0-hour sample was scheduled to be collected following dosed feed removal, but prior to offering untreated feed. Whole blood samples were collected via cardiac puncture from anesthetized mice.

### ANALYSIS METHOD

Blood and brain tissue samples were measured using gas chromatography with mass selective detection (GC/MSD). The target limit of quantitation (LOQ) for N-Butylbenzenesulfonamide (NBBS) (IV and gavage) in plasma was 2.5 ng/mL, for NBBS in brain was 25 ng/g tissue. Samples below the LOQ were designated as below the limit of quantitation (BLOQ).

### TK\_INTRAVENOUS BRAIN

#### 20 mg/kg Male and Female

Mice were give a single intravenous dose in Cremophor:ethanol:deionized water (1:1:8) vehicle and allowed food and water ad libitum. Blood and brain samples were collected at 11 time points post-administration with n=3 per time point. Time points were pre-dose, 2, 5, 10, 15, 20, 30, 45, 60, 120, 180, and 240 min post-dose.

## TK\_PARAMETERS PROTOCOL (cont'd)

### TK\_GAVAGE BRAIN

## 20 mg/kg Male and Female

Mice were given a single oral gavage dose in 0.5% methylcellulose in deionized water vehicle and allowed food and water ad libitum. Blood and brain samples were collected at 11 time points post-administration with n=3 per time point. Time points were Pre-dose, 2, 5, 10, 15, 20, 30, 45, 60, 120, 240, and 480 min post-dose.

### 60 mg/kg, 200 mg/kg Male and Female

Mice were given a single oral gavage dose in 0.5% methylcellulose in deionized water vehicle and allowed food and water ad libitum. Blood and brain samples were collected at 11 time points post-administration with n=3 per time point. Pre-dose, 5, 10, 20, 30, 45, 60, 120, 240, 480, 720, and 1440 min post-dose.